Cordis trial compares Nevo with Abbott's Xience

Justine Varieur Cadet | | Cardiovascular Business | Interventional Cardiology
Johnson & Johnson subsidiary Cordis, has launched a global, head-to-head, randomized clinical trial to compare its Nevo sirolimus-eluting coronary stent with the Xience V everolimus-eluting coronary stent from Abbott.

Nevo is a drug-eluting stent utilizing reservoir (RES) technology, which Cordis acquired from Conor Medsystems in 2007. RES technology incorporates hundreds of small reservoirs, each acting as a depot into which drug-polymer compositions are loaded, according to the Bridgewater, N.J.-based Cordis. The design allows a stent with a surface that is 75 percent bare metal upon insertion to become fully bare metal following drug delivery and polymer bio-resorption in approximately three months.

Cordis said NEVO II will be a global, randomized, non-inferiority trial of approximately 2,000 patients with coronary artery disease. The company said it hopes the results will provide long-term data in support of a pre-market application with the FDA; it plans to meet with regulatory authorities soon to finalize the design for the trial.

Cordis and the Menlo Park, Calif.-based Conor Medsystems are co-sponsors of the study.

Justine Varieur Cadet

Related Content

Cardiologists reflect on developing primary PCI in face of criticism and pushback
How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
IVUS-guided PCI reduces risks in patients with diabetes
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
LAAC with Watchman FLX reduces bleeding risks after AFib ablation

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."